Koers Xeris Biopharma Holdings, Inc. Nasdaq
Aandelen
XERS
US98422L1070
Farmaceutische producten
Omzet 2024 * | 184 mln. 172 mln. | Omzet 2025 * | 219 mln. 205 mln. | Marktkapitalisatie | 259 mln. 243 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -55 mln. -51,44 mln. | Nettowinst (verlies) 2025 * | -27 mln. -25,25 mln. | EV/omzet 2024 * | 1,41 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,18 x |
K/w-verhouding 2024 * |
-4,55
x | K/w-verhouding 2025 * |
-9,55
x | Werknemers | 377 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,26% |
Recentste transcriptie over Xeris Biopharma Holdings, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 60 | 01-01-05 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 05-10-21 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 01-01-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 05-10-21 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 05-10-21 |
Marla Persky
BRD | Director/Board Member | 68 | 05-10-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |